Rockwell Medical, Inc. Q2 2025 Earnings Recap

RMTI Q2 2025 August 14, 2025

Get alerts when RMTI reports next quarter

Rockwell Medical reported a 38% decline in net sales for Q2 2025, largely due to the transition of their largest customer to a new supplier, yet managed to maintain a positive cash flow from operations.

Earnings Per Share Beat

$-0.05 vs $-0.05 est.

+0.0% surprise

Revenue Miss

16071000 vs 16332000 est.

-1.6% surprise

Market Reaction

1-Day -2.86%

5-Day +10.48%

30-Day +60.0%

See RMTI alongside your other holdings

Add to your portfolio — free

Key Takeaways

Net sales for Q2 2025 decreased to $16.1 million, down from $25.8 million in Q2 2024.
Over 80% of customers are secured under long-term contracts, providing stability amidst a challenging transition year.
The company achieved adjusted EBITDA improvement, reducing losses from a negative $400,000 in Q1 to negative $200,000 in Q2 2025.
New multiyear agreements with significant clients show potential for revenue recovery in the coming quarters.
Guidance for 2025 remains unchanged with expected net sales between $65 million and $70 million.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit RMTI on AllInvestView.

Next Q3 2025